Emergent BioSolutions (Emergent BioSolutions) Interest Coverage

: 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Emergent BioSolutions's Operating Income for the three months ended in Dec. 2023 was $-44 Mil. Emergent BioSolutions's Interest Expense for the three months ended in Dec. 2023 was $-22 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Emergent BioSolutions's Interest Coverage or its related term are showing as below:

EBS's Interest Coverage is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 12.35
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emergent BioSolutions Interest Coverage Historical Data

The historical data trend for Emergent BioSolutions's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

2.97

14.01

11.10

Emergent BioSolutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															-	-	0.48	-	-

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions Interest Coverage Distribution

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Interest Coverage falls into.

Emergent BioSolutions Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emergent BioSolutions's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Emergent BioSolutions's Interest Expense was $-88 Mil. Its Operating Income was $-202 Mil. And its Long-Term Debt & Capital Lease Obligation was $447 Mil.

Emergent BioSolutions did not have earnings to cover the interest expense.

Emergent BioSolutions's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Emergent BioSolutions's Interest Expense was $-22 Mil. Its Operating Income was $-44 Mil. And its Long-Term Debt & Capital Lease Obligation was $447 Mil.

Emergent BioSolutions did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Emergent BioSolutions (NYSE:EBS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Emergent BioSolutions Interest Coverage Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (Emergent BioSolutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

ER4:Germany ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Executives

Neal Franklin Fowler	director	C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel	officer: SVP, Bioservices	400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii	officer: Interim CEO	EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams	officer: SVP, Products Business	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal	director	C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen	officer: EVP, Quality & Ethics, and CPL	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox	officer: EVP, Ext Aff, GC, Corp Sec	400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl	officer: EVP, Chief Financial Officer	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey	officer: EVP, BioDefense Division	2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer	officer: Interim, EVP, BioSciences	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850